ASO Author Reflection: Radiomics-Based Prediction for the Responder to First-Line Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastasis

被引：0
|
作者：
Ryota Nakanishi
Eiji Oki
Hirofumi Hasuda
Eiki Sano
Yu Miyashita
Akihiro Sakai
Naomichi Koga
Naotaka Kuriyama
Kentaro Nonaka
Yoshiaki Fujimoto
Tomoko Jogo
Kentaro Hokonohara
Qingjiang Hu
Yuichi Hisamatsu
Koji Ando
Yasue Kimura
Tomoharu Yoshizumi
Masaki Mori
机构：
[1] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2986 / 2987
页数：1
相关论文
共 50 条
  • [1] ASO Author Reflection: Radiomics-Based Prediction for the Responder to First-Line Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastasis
    Nakanishi, Ryota
    Oki, Eiji
    Hasuda, Hirofumi
    Sano, Eiki
    Miyashita, Yu
    Sakai, Akihiro
    Koga, Naomichi
    Kuriyama, Naotaka
    Nonaka, Kentaro
    Fujimoto, Yoshiaki
    Jogo, Tomoko
    Hokonohara, Kentaro
    Hu, Qingjiang
    Hisamatsu, Yuichi
    Ando, Koji
    Kimura, Yasue
    Yoshizumi, Tomoharu
    Mori, Masaki
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (06) : 2986 - 2987
  • [2] Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy
    Nakanishi, Ryota
    Oki, Eiji
    Hasuda, Hirofumi
    Sano, Eiki
    Miyashita, Yu
    Sakai, Akihiro
    Koga, Naomichi
    Kuriyama, Naotaka
    Nonaka, Kentaro
    Fujimoto, Yoshiaki
    Jogo, Tomoko
    Hokonohara, Kentaro
    Hu, Qingjiang
    Hisamatsu, Yuichi
    Ando, Koji
    Kimura, Yasue
    Yoshizumi, Tomoharu
    Mori, Masaki
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (06) : 2975 - 2985
  • [3] Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy
    Ryota Nakanishi
    Eiji Oki
    Hirofumi Hasuda
    Eiki Sano
    Yu Miyashita
    Akihiro Sakai
    Naomichi Koga
    Naotaka Kuriyama
    Kentaro Nonaka
    Yoshiaki Fujimoto
    Tomoko Jogo
    Kentaro Hokonohara
    Qingjiang Hu
    Yuichi Hisamatsu
    Koji Ando
    Yasue Kimura
    Tomoharu Yoshizumi
    Masaki Mori
    Annals of Surgical Oncology, 2021, 28 : 2975 - 2985
  • [4] Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
    Giannini, Valentina
    Pusceddu, Laura
    Defeudis, Arianna
    Nicoletti, Giulia
    Cappello, Giovanni
    Mazzetti, Simone
    Sartore-Bianchi, Andrea
    Siena, Salvatore
    Vanzulli, Angelo
    Rizzetto, Francesco
    Fenocchio, Elisabetta
    Lazzari, Luca
    Bardelli, Alberto
    Marsoni, Silvia
    Regge, Daniele
    CANCERS, 2022, 14 (01)
  • [5] Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer
    Yamamoto, Seiji
    Fujii, Hironori
    Murayama, Kotaro
    Iihara, Hirotoshi
    Watanabe, Daichi
    Yamada, Yunami
    Kobayashi, Ryo
    Kiyama, Shigeru
    Makiyama, Akitaka
    Urano, Kimihiko
    Matsuhashi, Nobuhisa
    Matsuura, Katsuhiko
    Suzuki, Akio
    ANTICANCER RESEARCH, 2023, 43 (11) : 5099 - 5105
  • [6] Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer
    Chibaudel, B.
    Tournigand, C.
    Bonnetain, F.
    Andre, T.
    Lledo, G.
    Maindrault-Goebel, F.
    Larsen, A. K.
    Louvet, C.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
    Tada, K.
    Shoji, H.
    Kitano, S.
    Nishimura, T.
    Shimada, Y.
    Nagashima, K.
    Ito, A.
    Honma, Y.
    Iwasa, S.
    Okita, N.
    Takashima, A.
    Kato, K.
    Yamada, Y.
    Katayama, N.
    Boku, N.
    Heike, Y.
    Hamaguchi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
  • [8] Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan- and/or oxaliplatin-based chemotherapy
    Catalano, V.
    D'Emidio, S.
    Loupakis, F.
    Graziano, F.
    Torresi, U.
    Mari, D.
    Bisonni, R.
    Giordani, P.
    Giustini, L.
    Falcone, A.
    Silva, R. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
    Gerger, Armin
    El-Khoueiry, Anthony
    Zhang, Wu
    Yang, Dongyun
    Singh, Harpreet
    Bohanes, Pierre
    Ning, Yan
    Winder, Thomas
    LaBonte, Melissa J.
    Wilson, Peter M.
    Benhaim, Leonor
    Paez, David
    El-Khoueiry, Rita
    Absenger, Gudrun
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5783 - 5792
  • [10] Who Will Benefit? Using Radiomics to Predict Response to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases
    Daniel Brock Hewitt
    Timothy M. Pawlik
    Jordan M. Cloyd
    Annals of Surgical Oncology, 2021, 28 : 2931 - 2933
12345